KDR and neoplasm: Moreover, double IF analyses using antibodies against EGF and cell type-specific markers (EpCAM for tumor cells, F4/80 for macrophages, FSP1 for fibroblasts, and VEGFR2 for endothelial cells) in relapsed H460 xenograft tumors upon the completion of combinatorial chemotherapy confirmed the upregulation of EGF in EpCAM+ tumor cells (Figure 2J).